Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Eli Lilly And Co (LLY) vs McDonald's Corp (MCD) Price & Performance

Eli Lilly And CoTrade
McDonald's CorpTrade

Price performance (Past 24H)

Key statistics

Eli Lilly And Co vs McDonald's Corp — how do they compare? Eli Lilly And Co trades at $1,214.89 (market cap $1.10T), while McDonald's Corp trades at $273.96 (market cap $193.70B). The key difference: Eli Lilly And Co is far larger — about 5.7× McDonald's Corp's market cap, and McDonald's Corp pays the higher dividend (2.72%). Which is the better fit depends on your goals.

LLYMCD
Market Cap
$1.10T$193.70B
Sector
HealthConsumer Cyclical
52-Week High
$1.24K$341.06
52-Week Low
$639.43$262.80
Enterprise Value
$1.14T$247.47B
Dividend Yield
0.56%2.72%
Volume
2,230,036

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,185.71, down 0.59% on the day, with a bullish technical signal from moving averages and strong fundamental momentum. The company reported Q2 2026 revenue growth of 48% to $23 billion, beating estimates, driven by demand for Mounjaro and Zepbound. Valuation ratios like P/E of 39.8 and P/S of 13.34 reflect high growth expectations, while profitability remains robust with a net income margin of 33.53%.

Outlook is positive due to pipeline advancements like retatrutide and raised 2026 guidance, but risks include competitive pressures and regulatory scrutiny. Analysts are bullish with a consensus price target of $1,380, citing sustained double-digit growth and market leadership in weight-loss drugs as key drivers for upside.

McDonald's Corp

McDonald's (MCD) trades at $274.15, down slightly by 0.12% on the day, with technical indicators showing a neutral overall signal. The company demonstrates strong fundamentals with consistent revenue growth, reaching $26.89 billion in 2025, and robust profitability with a 31.72% net income margin. Recent earnings have consistently beaten expectations, and the company has announced a new global growth strategy focused on automation and menu innovation to drive future performance.

The outlook for MCD is positive, supported by strong analyst consensus with a $322.45 price target implying significant upside. Key opportunities include the successful execution of its new growth plan and its defensive qualities in a challenging economy. Primary risks involve inflationary pressures on franchisee margins and intense competition in the quick-service restaurant sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY

About McDonald's Corp

McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.

Read more on MCD